BioDelivery Sciences (BDSI) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Despite Bunavail Stuggles, BioDelivery Sciences (BDSI) Should Sell Asset to Strategic Buyer - Piper Jaffray
August 10, 2016 11:15 AM EDTPiper Jaffray analyst David Amsellem noted BioDelivery Sciences International (NASDAQ: BDSI) Bunavail is still struggling but said the company should explore a sale of the asset to a strategic buyer.
Amsellem commented, "BioDelivery Sciences reported 2Q16 net loss per share of ($0.31) on... More



